Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline

dc.contributor.authorMielke, Michelle M.
dc.contributor.authorAakre, Jeremiah A.
dc.contributor.authorAlgeciras-Schimnich, Alicia
dc.contributor.authorProctor, Nicholas K.
dc.contributor.authorMachulda, Mary M.
dc.contributor.authorEichenlaub, Udo
dc.contributor.authorKnopman, David S.
dc.contributor.authorVemuri, Prashanthi
dc.contributor.authorGraff-Radford, Jonathan
dc.contributor.authorJac, Clifford R., Jr.
dc.contributor.authorPetersen, Ronald C.
dc.contributor.authorDage, Jeffrey L.
dc.contributor.departmentNeurology, School of Medicine
dc.date.accessioned2024-09-11T18:18:18Z
dc.date.available2024-09-11T18:18:18Z
dc.date.issued2022
dc.description.abstractIntroduction: The prognostic utility of cerebrospinal fluid (CSF) phosphorylated tau 217 (p-tau217) and p-tau181 is not understood. Methods: Analyses included 753 Mayo Clinic Study on Aging participants (median age = 71.6; 57% male). CSF amyloid beta (Aβ)42 and p-tau181 were measured with Elecsys immunoassays. CSF p-tau181 and p-tau217 were also measured with Meso Scale Discovery (MSD). We used Cox proportional hazards models for risk of mild cognitive impairment (MCI) and linear mixed models for risk of global and domain-specific cognitive decline and cortical thickness. Analyses were stratified by elevated brain amyloid based on CSF Aβ42 or amyloid positron emission tomography for those with imaging. Results: CSF p-tau217 was superior to p-tau181 for the diagnosis of Alzheimer's disease (AD) pathology. CSF MSD p-tau181 and p-tau217 were associated with risk of MCI among amyloid-positive individuals. Differences between CSF p-tau measures predicting cortical thickness were subtle. Discussion: There are subtle differences for CSF p-tau217 and p-tau181 as prognostic AD markers.
dc.eprint.versionAuthor's manuscript
dc.identifier.citationMielke MM, Aakre JA, Algeciras-Schimnich A, et al. Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline. Alzheimers Dement. 2022;18(4):602-611. doi:10.1002/alz.12415
dc.identifier.urihttps://hdl.handle.net/1805/43278
dc.language.isoen_US
dc.publisherWiley
dc.relation.isversionof10.1002/alz.12415
dc.relation.journalAlzheimer’s & Dementia
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectCerebrospinal fluid
dc.subjectPhosphorylated tau
dc.subjectBiomarker
dc.subjectPrognosis
dc.subjectCognitive decline
dc.subjectMild cognitive impairment
dc.subjectDementia
dc.titleComparison of CSF phosphorylated tau 181 and 217 for cognitive decline
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Mielke2022Comparison-AAM.pdf
Size:
831.86 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: